Transgene S.A. (Euronext: TNG)

https://www.transgene.fr

Transgene (Euronext: TNG) is a biotechnology company focused on designing and developing targeted immunotherapies for the treatment of cancer. Transgene’s programs utilize viral vector technology with the goal of indirectly or directly killing cancer cells. The Company’s clinical-stage programs consist of a portfolio of therapeutic vaccines and oncolytic viruses: TG4050, the first individualized therapeutic vaccine based on the myvac® platform, TG4001 for the treatment of HPV-positive cancers, as well as TG6002, BT-001 and TG6050, three oncolytic viruses based on the Invir.IO® viral backbone. With Transgene’s myvac® platform, therapeutic vaccination enters the field of precision medicine with a novel immunotherapy that is fully tailored to each individual. The myvac® approach allows the generation of a virus-based immunotherapy that encodes patient-specific mutations identified and selected by Artificial Intelligence capabilities provided by its partner NEC. With its proprietary platform Invir.IO®, Transgene is building on its viral vector engineering expertise to design a new generation of multifunctional oncolytic viruses. *

	Start	1979-01-01 established
	Group	Mérieux (Group)
	Industry	therapeutic vaccine
	Industry 2	immunotherapy
	Person	Riva, Alessandro (Transgene 202306– CEO before Chairman before Intima Bioscience + Ichnos Sciences + Gilead + Novartis)
	Person 2	Bloom, Steven (Transgene 202202– US-based CBO before Boston Pharmaceuticals + Vavotar Life Sciences + Verastem Oncology)

	Region	Strasbourg
	Country	France
	Street	400 Boulevard Gonthier d’Andernach Parc d’Innovation d’Illkirch
	City	67405 Illkirch
	Tel	+33-3-8827-9100
		Address record changed: 2024-01-05

Basic data	Employees	D: 101 to 500 (2006-12-31)
	Currency	EUR
	Annual sales	28,019,000 (revenues, total (2007) 2007-12-31)
	Profit	-5,521,000 (2007-12-31)
	Cash	84,100,000 (2014-09-30)

		* Document for »About Section«: Transgene S.A.. (5/5/23). "Press Release: Transgene Announces New Leadership Structure to Accelerate the Development of its Innovative Immunotherapy Portfolio". Strasbourg.

		Record changed: 2024-02-12